About: Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.36 (-20.94%)
Status: Delisted — removed_from_provider. This asset is no longer trading; historical data is shown.
CYCN NASDAQ Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc share price
CYCN price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
CYCN price performance
CYCN Market Signals